Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis

Kao,Johnny; Timmins,Jonathan; Ozao‑Choy,Junko; Packer,Stuart

doi:10.3892/ol.2016.4851

Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis

Authors:
- Johnny Kao
- Jonathan Timmins
- Junko Ozao‑Choy
- Stuart Packer
View Affiliations

Affiliations: Department of Radiation Oncology, Good Samaritan Hospital Medical Center, West Islip, NY 11795, USA, Department of Surgery, University of California, Los Angeles (UCLA) Medical Center, Los Angeles, CA 90502, USA, Division of Medical Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
Published online on: July 13, 2016 https://doi.org/10.3892/ol.2016.4851
Pages: 2139-2144

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is considerable interest in deploying stereotactic body radiotherapy in combination with immune therapy for patients with extracranial oligometastases. In addition to angiogenesis inhibition, sunitinib appears to mediate antitumor immunity through effects on circulating monocytic cells. The current study investigated the effects of combined sunitinib and stereotactic radiotherapy on hematopoiesis. As part of a phase I/II clinical trial utilizing concurrent sunitinib (25‑50 mg on days 1‑28) and image‑guided radiation therapy (40-50 Gy in 10 fractions starting on days 8‑19) for patients with metastatic cancer, the complete blood count, platelet count and automatic differential were performed pretreatment and on days 8 and 19. On average, sunitinib monotherapy for 7 days resulted in a 33% decrease in monocytes and an 18% decrease in neutrophils (P<0.01 for all). Compared to sunitinib alone, combined sunitinib and radiation resulted in a further decrease in neutrophils, lymphocytes and platelets (P<0.05). Following sunitinib and radiation treatment, a greater than average decrease in monocytes (≥200/µl) was associated with a significant increase in progression‑free and overall survival times. This exploratory study provides further evidence that monocytes represent a potential biomarker in patients with solid tumors treated with sunitinib.

View Figures

View References

1	Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, et al: Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 118:2962–2970. 2012. View Article : Google Scholar : PubMed/NCBI
2	Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 366:925–931. 2012. View Article : Google Scholar : PubMed/NCBI
3	Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 124:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
4	Twyman-Saints Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 520:373–377. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY and Chen SH: The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69:2514–2522. 2009. View Article : Google Scholar : PubMed/NCBI
6	Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 26:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
7	Faivre S, Demetri G, Sargent W and Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 6:734–745. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 15:2148–2157. 2009. View Article : Google Scholar : PubMed/NCBI
9	Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G and Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63:4009–4016. 2003.PubMed/NCBI
10	Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH and Cesaretti JA: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: Acute toxicity and preliminary response. Cancer. 115:3571–3580. 2009. View Article : Google Scholar : PubMed/NCBI
11	Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, et al: Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One. 7:e369792012. View Article : Google Scholar : PubMed/NCBI
12	Kao J, Chen CT, Tong CC, Packer SH, Schwartz M, Chen SH and Sung MW: Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: Final report of a prospective clinical trial. Target Oncol. 9:145–153. 2014. View Article : Google Scholar : PubMed/NCBI
13	Chen HM, Ma G, Gildener-Leapman N, Eisenstein S, Coakley BA, Ozao J, Mandeli J, Divino C, Schwartz M, Sung M, et al: Myeloid derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy. Clin Cancer Res. 21:4073–4085. 2015. View Article : Google Scholar : PubMed/NCBI
14	Chin-Yee IH, Keeney M, Johnson K, Brown W, Wolfe N and Kaplan S: White blood cell flagging rates of the Coulter LH 750 analyzer compared with the Coulter Gen.s Hematology Analyzer. Laboratory Hematology. 7:211–216. 2001.
15	Ellis RE: The distribution of active bone marrow in the adult. Phys Med Biol. 5:255–258. 1961. View Article : Google Scholar : PubMed/NCBI
16	Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP and Jain RK: Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin Cancer Res. 17:918–927. 2011. View Article : Google Scholar : PubMed/NCBI
17	Gonzalez-Garcia I, Solé RV and Costa J: Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA. 99:13085–13089. 2002. View Article : Google Scholar : PubMed/NCBI
18	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
19	Tannock IF: Conventional cancer therapy: Promise broken or promise delayed? Lancet. 351(Suppl 2): SII9–SI16. 1998. View Article : Google Scholar : PubMed/NCBI
20	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
21	Morabito A, De Maio E, Di Maio M, Normanno N and Perrone F: Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist. 11:753–764. 2006. View Article : Google Scholar : PubMed/NCBI
22	Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, et al: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 13:2643–2650. 2007. View Article : Google Scholar : PubMed/NCBI
23	Rini BI, Choueiri TK, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R and Bukowski RM: Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer. 113:1309–1314. 2008. View Article : Google Scholar : PubMed/NCBI
24	van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, et al: Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res. 14:5884–5892. 2008. View Article : Google Scholar : PubMed/NCBI
25	Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
26	Formenti SC and Demaria S: Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst. 105:256–265. 2013. View Article : Google Scholar : PubMed/NCBI
27	Mac Manus M, Lamborn K, Khan W, Varghese A, Graef L and Knox S: Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model. Blood. 89:2303–2310. 1997.PubMed/NCBI
28	Leighl NB: Sunitinib: The next advance in small-cell lung cancer? J Clin Oncol. 33:1637–1639. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, et al: Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J Cancer. 112:1199–1205. 2015. View Article : Google Scholar : PubMed/NCBI
30	Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH and Cohen PA: Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70:3526–3536. 2010. View Article : Google Scholar : PubMed/NCBI
31	Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
32	Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15:700–712. 2014. View Article : Google Scholar : PubMed/NCBI